Injectable formulations comprising a liplophilic beta-2 adrenergic receptor agonist for regional adiposity reduction

An injectable formulation for regional adiposity reduction comprises/consists essentially of (a) an active ingredient that consists essentially of an adipose tissue reducing amount of one or more lipophilic long acting selective beta-2 adrenergic receptor agonists or salts, solvates or polymorphs thereof and (b) one or more subcutaneously acceptable inactive ingredients. Preferably, the lipophilic long acting selective beta-2 adrenergic receptor agonist is selected from the group including salmeterol, preferably salmeterol xinafoate and formoterol, preferably formoterol fumerate. The use of the formulation for cosmetic reduction of adiposity, for inducing lipolysis in adipose tissue, for aesthetic treatment of contour defects comprising abdominal bulging and for use in treating thyroid eye disease by contacting a targeted fat deposit in the eye is also outlined. The formulation may be formulated to contain between 5ng and 20µg of salmeterol xinafoate which may be administered once per week, once per month or once every two weeks. Preferably the formulation is free from glucocorticosteroids.